Skip to main content
. 2021 Sep 9;13(18):4536. doi: 10.3390/cancers13184536

Figure 5.

Figure 5

Probability of survival in patients treated with AML-PPLLSG 98, AML-BFM 2004 Interim, and AML-BFM 2012 Registry with and without hematopoietic stem cell transplantation (HSCT). The patients with event-free survival shorter than 4 months were excluded from the analysis: (a) overall survival; (b) event free survival; (c) relapse free survival.